Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): HQ2231 has been approved for clinical trials.
Baicheng Pharmaceuticals (301096.SZ) announcement, the company's wholly-owned subsidiary Baicheng Pharmaceuticals (Zhuhai Hengqin) Co., Ltd. recently...
Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that its wholly-owned subsidiary, Hangzhou Bio-Sincerity Pharma-Tech (Zhuhai Hengqin) Co., Ltd., has recently received the National Medical Products Administration (NMPA) approval notification for clinical trials. The company's independently developed drug, HQ2231, will undergo clinical trial research. The drug is indicated for schizophrenia.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
